Рembrolizumab as second line therapy for hepatocellular patient

The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or those with the impaired liver function can get an appropriate drug therapy. This clinical observation illustrates the long-term effect of pembrol...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: I. A. Dzhanyan, V. V. Breder, O. I. Borisova, K. K. Laktionov
Format: Artigo
Jezik:Russo
Izdano: Remedium Group LLC 2021-12-01
Serija:Медицинский совет
Teme:
hepatocellular carcinoma
second line
checkpoint inhibitors
pembrolizumab
sorafenib
Online dostop:https://www.med-sovet.pro/jour/article/view/6593
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki